FDA pushes missing trials
The FDA has asked roughly 2,200 drug developers to publish missing clinical‑trial results after an internal check found nearly 30% of studies likely subject to mandatory reporting lacked posted results. This outreach was reported across trade outlets and national press as a coordinated push to close gaps in the public trial record. (statnews.com) (biospace.com)
The Food and Drug Administration has told more than 2,200 drug and device sponsors and researchers to post missing clinical-trial results to the public record. (fda.gov) The agency said on April 13 that an internal review found 29.6% of studies “highly likely” to face mandatory reporting rules had no results submitted to ClinicalTrials.gov. The outreach covered more than 3,000 registered trials. (fda.gov) Those messages went out on March 30, 2026, to companies and investigators that appear either not to have filed required results or not to have finished the National Library of Medicine’s quality-control review. The Food and Drug Administration called the letters an extra step before deciding whether to pursue enforcement. (fda.gov) ClinicalTrials.gov is the federal database where sponsors are supposed to post basic trial details and summary results so doctors, patients, and researchers can see what happened. Federal law has required that reporting system since 2007, and the current rule took effect in 2017. (clinicaltrials.gov) For many covered trials, the deadline is one year after the trial’s primary completion date, not after a journal article appears. The rules generally apply to “applicable clinical trials” involving Food and Drug Administration-regulated products, while Phase 1 drug trials and small device feasibility studies are excluded. (clinicaltrials.gov) (ecfr.gov) The Food and Drug Administration said missing results create gaps in the public record and can skew the picture of drug development by making failures harder to see. Commissioner Marty Makary said sponsors have an ethical duty to disclose results “regardless of the data’s influence on the company’s share price.” (fda.gov) (biospace.com) If sponsors still do not comply, the agency can move from reminder letters to pre-notices and then notices of noncompliance, which can lead to civil money penalties. Trade outlets said the potential fines can exceed $10,000 a day for continued failure to report. (fda.gov 1) (fda.gov 2) (clinicaltrialsarena.com) The push fits a broader transparency campaign at the agency under Makary. In July 2025, the Food and Drug Administration published more than 200 complete response letters, the decision memos it sends when it rejects drug applications. (fda.gov) Not everyone expects the letters alone to fix the backlog. STAT quoted one expert saying the move looked “more symbolic than substantive,” but the agency has now put thousands of overdue records on notice at once. (statnews.com)
